XML 156 R73.htm IDEA: XBRL DOCUMENT
v3.20.4

Significant transactions (Details) € in Millions |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2020 USD ($) | Jan. 31, 2020 EUR (€) | Jan. 06, 2020 USD ($) | Nov. 23, 2019 USD ($) | Nov. 11, 2019 USD ($) | Nov. 11, 2019 EUR (€) | Jul. 01, 2019 USD ($) | May 07, 2019 USD ($) | Apr. 08, 2019 USD ($) | Dec. 21, 2018 USD ($) | May 15, 2018 USD ($) | Mar. 27, 2018 USD ($) | Jan. 22, 2018 USD ($) | Mar. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2020 SFr / shares | Jan. 31, 2020 EUR (€) | Nov. 11, 2019 EUR (€) | Apr. 09, 2019 USD ($) | Mar. 06, 2019 USD ($) | Sep. 06, 2018 USD ($) | Apr. 06, 2018 USD ($) | Oct. 30, 2017 USD ($)
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,173,000,000 | $ 4,124,000,000 | $ 13,946,000,000 |  |  |  |  |  |  |  |
Profit (loss) from discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,590,000,000 | (186,000,000) |  |  |  |  |  |  |  |
Par value per share | SFr / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | SFr 0.50 |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (792,000,000) | (2,042,000,000) | (1,224,000,000) |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 36,809,000,000 | 28,787,000,000 |  |  |  |  |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 48,659,000,000 | 47,498,000,000 | 44,833,000,000 |  |  |  |  |  |  |  |
Borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 28,531,000,000 | 22,355,000,000 |  |  |  |  |  |  |  |  |
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net |  |  |  |  |  |  |  |  | $ 4,691,000,000 |  |  |  |  |  |  |  | 4,691,000,000 |  |  |  |  |  |  |  |  |
Alcon [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Decrease of distribution liability |  |  |  |  |  |  |  |  | $ 3,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest shares received |  |  |  |  |  |  |  |  | 4.70% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche Holding AG, Switzerland |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,233,000,000 |  |  |  |  |  |  |  |  |  |
Sandoz | Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, divestment-date fair value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000,000 |  |
Depreciation, property, plant and equipment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 38,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Amortisation, intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  | 102,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Impairment loss recognised in profit or loss, intangible assets and goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (42,000,000) |  |  |  |  |  |  |  |  |  |  |  |
Advanced Accelerator Applications (AAA) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  |  |  |  |  |  |  | $ (3,900,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  |  |  |  | 1,900,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue of acquiree since acquisition date |  |  |  |  |  |  |  |  |  |  |  |  | 400,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue of acquiree full year |  |  |  |  |  |  |  |  |  |  |  |  | $ 400,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Share capital in tender offer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00%
Cash offer per ordinary share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 41
Cash offer per ADS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 82
Number of ordinary share per ADS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2
Value of equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,900,000,000
Percentage of share capital tendered at the expiration of the tender offer |  |  |  |  |  |  |  |  |  |  |  |  | 97.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  |  |  |  | $ 600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Total percentage of share capital tendered after the subsequent offering period of the tender offer |  |  |  |  |  |  |  |  |  |  |  |  | 98.70% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of share capital tendered at the subsequent offering period of the tender offer |  |  |  |  |  |  |  |  |  |  |  |  | 1.80% |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration paid for share capital tendered at the subsequent offering period of the tender offer |  |  |  |  |  |  |  |  |  |  |  |  | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Proportion of ownership interest in subsidiary |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 99.20% |  |  |  |  |  |  |  |  |  |
Aspen Global Incorporated | Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value | $ 324,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 294.0 |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents | (273,000,000) | € (247.0) |  |  | $ (336,000,000) | € (300.0) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid consisting of cash and cash equivalents upfront payment | (303,000,000) | (274.0) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent liabilities recognised as of acquisition date | 51,000,000 |  |  |  | $ 112,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 47.0 | € 100.0 |  |  |  |  |
Identifiable assets acquired (liabilities assumed) | 238,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill | 86,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other net assets | 26,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill | 196,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone maximum payments | 77,000,000 | 70.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customary purchase price adjustment | $ 30,000,000 | € 27.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
The Medicines Company | Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  | $ 9,600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  | $ (9,600,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  | 7,100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  | 2,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash offer per ordinary share |  |  |  | $ 85.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  | 1,400,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  | $ 8,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AveXis, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  |  |  |  |  | $ (8,700,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  |  | 7,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  |  |  |  | 1,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash offer per ordinary share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 218 |
Other net assets |  |  |  |  |  |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  |  | 1,600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  | $ 8,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Endocyte |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  |  |  |  |  |  |  | $ 2,100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  |  |  |  | (2,100,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  | 1,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  |  |  | 600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash offer per ordinary share |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other net assets |  |  |  |  |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  | $ 1,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK Consumer Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Divested interest in associate |  |  |  |  |  |  |  |  |  |  |  | 36.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations |  |  |  |  |  |  |  |  |  |  |  | $ 12,994,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pre tax profit (loss) from divestment of business |  |  |  |  |  |  |  |  |  |  |  | $ 5,800,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Takeda Pharmaceutical Company Limited | Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  |  |  |  | $ 3,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  | (3,500,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid consisting of cash and cash equivalents upfront payment |  |  |  |  |  |  | (3,400,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent liabilities recognised as of acquisition date |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  | 3,600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue of acquiree since acquisition date |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue of acquiree full year |  |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  | 3,600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone maximum payments |  |  |  |  |  |  | 1,900,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customary purchase price adjustment |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IFM Tre, Inc. | Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  |  |  |  |  | $ 361,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  |  | (285,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent liabilities recognised as of acquisition date |  |  |  |  |  |  |  | 76,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  | 355,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  | $ 39,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Divested interest in associate |  |  |  |  |  |  |  | 9.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date |  |  |  |  |  |  |  | $ 33,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination |  |  |  |  |  |  |  | $ 14,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of voting equity interests acquired |  |  |  |  |  |  |  | 91.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Continuing operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,660,000,000 |  |  |  |  |  |  |  |
Discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Profit (loss) from discontinued operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,590,000,000 | (186,000,000) |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (858,000,000) |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  | $ 11,121,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,809,000,000 | $ 7,153,000,000 |  |  |  |  |  |  |  |
Dividend in kind distribution liability |  |  |  |  |  |  |  |  | 23,434,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed |  |  |  |  |  |  |  |  | 3,409,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,691,000,000 |  |  |  |  |  |  |  |  |
Discontinued operations | Alcon [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repayment of intercompany balances |  |  |  |  |  |  |  |  | $ (3,100,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,200,000,000 |  |  |
Dividend in kind distribution liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 26,400,000,000 |  |  |  |  |  |  |  |  |  |  |
Borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000,000 |  |  |
Net assets liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,100,000,000 |  |  |  |  |  |  |  |  |  |  |
Financial assets, at fair value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000,000 |  |  |  |
Additional borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 300,000,000 |  |  |
Discontinued operations | Alcon [member] | Borrowings, USD [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,800,000,000 |  |  |
Discontinued operations | Alcon [member] | Borrowings, EUR [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other borrowings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 400,000,000 |  |  |
Discontinued operations | PowerVision, Inc. | Alcon [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 424,000,000 |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (289,000,000) |  |  |  |  |  |  |  |  |  |  |
Contingent liabilities recognised as of acquisition date |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 135,000,000 |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 418,000,000 |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000 |  |  |  |  |  |  |  |  |  |  |
Other net assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000 |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 93,000,000 |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 505,000,000 |  |  |  |  |  |  |  |  |  |  |
Subsidiaries [member] | The Medicines Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proportion of ownership interest in subsidiary |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |

X
- Definition The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph p -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph f -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B67 -Subparagraph d -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B67_d_ii&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_AdditionalRecognitionGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2019-01-01 -Paragraph 118 -Subparagraph e -Clause vi -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2019-en-r&anchor=para_118_e_vi&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of outstanding funds that the entity is obligated to repay. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_55&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_Borrowings
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph IE72 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_IE72&doctype=Illustrative%20Examples -URIDate 2019-03-27 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2019-01-01 -Paragraph 81 -Subparagraph g -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2019-en-r&anchor=para_81_g_i&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DeferredTaxLiabilityAsset
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 16 -IssueDate 2019-01-01 -Paragraph 73 -Subparagraph e -Clause vii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2019-en-r&anchor=para_73_e_vii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 16 -IssueDate 2019-01-01 -Paragraph 75 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2019-en-r&anchor=para_75_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DepreciationPropertyPlantAndEquipment
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRIC -Number 17 -IssueDate 2019-01-01 -Paragraph 15 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2019-en-r&anchor=para_15&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of dividends payable by means of the distribution of non-cash assets to owners. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRIC -Number 17 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2019-en-r&anchor=para_16_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DividendsPayable
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value of financial assets. [Refer: At fair value [member]; Financial assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2019-01-01 -Paragraph 25 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2019-en-r&anchor=para_25&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_FinancialAssetsAtFairValue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The gain (loss) recognised as result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before the business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph p -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_p_ii&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph IE72 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_IE72&doctype=Illustrative%20Examples -URIDate 2019-03-27 + Details
Name: | ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2019-01-01 -Paragraph 118 -Subparagraph e -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2019-en-r&anchor=para_118_e_iv&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in dividends payable through a change in the fair value of non-cash assets held for distribution to owners. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRIC -Number 17 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2019-en-r&anchor=para_16_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2019-01-01 -Paragraph 118 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2019-en-r&anchor=para_118_e&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 54 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_54_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of assets less the amount of liabilities. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 1 -IssueDate 2019-01-01 -Paragraph IG63 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_IG63&doctype=Implementation%20Guidance -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_112_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_NetAssetsLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_112_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_OtherBorrowings
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The nominal value per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 79 -Subparagraph a -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_79_a_iii&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ParValuePerShare
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_PercentageOfVotingEquityInterestsAcquired
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2019-01-01 -Paragraph 40 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_40_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2019-01-01 -Paragraph 16 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_16&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2019-01-01 -Paragraph 33 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2019-en-r&anchor=para_33_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B12 -Subparagraph b -Clause vii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 82 -Subparagraph ea -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_82_ea&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 98 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_98_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProfitLossFromDiscontinuedOperations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 19B -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_112_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph q -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_RevenueOfAcquiree
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_AdditionalBorrowings
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This expresses the amount of cash Novartis paid to the owners of AAA per ADS. + References No definition available. + Details
Name: | nvs_CashOfferPerADS
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share. + References No definition available. + Details
Name: | nvs_CashOfferPerOrdinaryShare
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_CustomaryPurchasePriceAdjustment
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DivestmentDateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_NumberOfOrdinarySharePerADS
Namespace Prefix: | nvs_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_OtherNetAssets
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PercentageOfEquityInterestSharesReceived
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PercentageOfShareCapitalInTenderOffer
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_PotentialMilestoneMaximumPayments
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_PreTaxProfitLossFromDivestmentOfBusiness
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_RepaymentOfIntercompanyBalances
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueOfAcquireeFullYear
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_ValueOfEquity
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_AlconMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsAAAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_AveXisIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_EndocyteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_GSKConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_IFMTreInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsUSDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=nvs_BorrowingsEURMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_PowerVisionInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |